Celltrion biosimilars gain strong market share across Asia

Celltrion said Monday it continues to see solid prescription growth across Asian markets, with several of its key biosimilar products capturing leading market shares. Its flagship autoimmune disease treatment Remsima has established a dominant presence in multiple markets. According to clinical research provider IQVIA, as of the third quarter of 2025 Remsima held market shares of 93 percent in Singapore, 77 percent in Hong Kong, 73 percent in Thailand and 65 percent in Malaysia. Another autoimmu

By The Korea Herald